Evidence map›Paper›PMID 41227302›Full record

ArticleCells2025

LT1-3, a Slit2-Derived Peptide, Exhibits Anti-Tumor Activity and Improves Cisplatin Therapy.

Ting-Chien Wu, Chen-Yi Liao, Yu-Ying Lin, Shu-Ming Chuang, Szu-Yu Liu, Chi-Hsiang Wang, Shang-Er Su, Siang-Wei Wu, Ling-I Wang, Wei-Ting Chen and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ting-Chien WuInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.ORCID 0009-0006-1549-3903
Chen-Yi LiaoInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Yu-Ying LinInstitute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Shu-Ming ChuangInstitute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Szu-Yu LiuInstitute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Chi-Hsiang WangInstitute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Shang-Er SuInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Siang-Wei WuInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Ling-I WangInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Wei-Ting ChenInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Sheng-Wen ChengInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Yu-Tang HuangDepartment of Medical Laboratory and Biotechnology, Chung Shan Medical University, 110 Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.ORCID 0009-0000-7220-3411
Yao-Bin ZhengDepartment of Medical Laboratory and Biotechnology, Chung Shan Medical University, 110 Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.
Cheng-Yen ChuangInstitute of Medical and Molecular Toxicology, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.ORCID 0000-0002-8656-9462
Feng-Di LungDepartment of Chemistry, Tunghai University, Taichung, No. 1727, Sec. 4, Taiwan Boulevard, Taichung City 407224, Taiwan.
Jinghua Tsai ChangInstitute of Medicine, Chung Shan Medical University, 110, Sec. 1, Chien-Kuo N. Road, Taichung City 402306, Taiwan.

Funding

Chung Shan Medical University CSMU-INT-109-03; CSMU-INT-113-08Ministry of Science and Technology MOST 105-2320-B-040-031; MOST 106-2320-B-040-019; MOST 107-2320-B-040-023; MOST 108-2320-B-040-004; MOST 110-2320-B-040-027.
6 · The paper itself

Abstract

The Slit2/Robo signaling pathway acts as a tumor suppressor in various cancers. This study identified an 8-amino acid peptide, LT1-3, derived from the Slit2 LamG domain, and demonstrated its ability to inhibit lung cancer cell proliferation and invasion independently of Robo receptors. Notably, LT1-3 was non-toxic to normal cells (Beas-2B, MRC5, and HUVECs). Combination treatment of LT1-3 and cisplatin synergistically inhibited the proliferation of lung cancer cells (CL1-5, A549, H1355, H460, H23, H661), but had no inhibitory effect on H1299 and H1975. Furthermore, combination therapy prolonged the median survival of tumor-bearing immunodeficient nude mice from 27.5 days (control) to 37.5 days (LT1-3 or cisplatin) and further to 47.5 days (LT1-3/cisplatin combination). The tumor suppressor

Indexed as

Antineoplastic AgentsCisplatinIntercellular Signaling Peptides and ProteinsLung NeoplasmsNerve Tissue ProteinsPeptide FragmentsAnimalsCell Line, TumorCell ProliferationDrug SynergismFemaleHumansMiceMice, NudeSlit Homolog 2 ProteinTumor Suppressor Protein p53Antineoplastic AgentsCisplatinIntercellular Signaling Peptides and ProteinsNerve Tissue ProteinsPeptide FragmentsSlit Homolog 2 ProteinTumor Suppressor Protein p53APR246CisplatinJNK1LT1-3p53Slit2

Identifiers

PMID41227302
PMCPMC12607519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.